Emicizumab manufacturers
- Emicizumab
-
- $1390.00
-
2026-07-08
- CAS:1610943-06-0
- Purity: 95.9% (SEC-HPLC)
- Supply Ability: 10g
|
| | Emicizumab Basic information |
| Product Name: | Emicizumab | | Synonyms: | Emicizumab;Research Grade Emicizumab (DHB87901);Emicizumab (anti-Factor IX);ACE 910|||RO 5534262;Research Grade Emicizumab;Imicizumab | | CAS: | 1610943-06-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Emicizumab Structure]() |
| | Emicizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Emicizumab Usage And Synthesis |
| Uses | Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research[1]. | | in vivo | Emicizumab (1.5-10 mg/kg, IV, 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia A bleeding model, with an FVIII equivalence of 9 U/dL[1].
Emicizumab (3 mg/kg, IV) provides additive hemostatic activity when given in combination with low-dose FVIII (10 U/dL)[1].
| Animal Model: | FVIII-deficient mice[1] | | Dosage: | 1.5-10 mg/kg | | Administration: | IV, 24 hours before tail-clip bleeding was performed | | Result: | Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice. |
| | References | [1] Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020 Aug 6;136(6):740-748. DOI:10.1182/blood.2019004334 |
| | Emicizumab Preparation Products And Raw materials |
|